Success in translational research: lessons from the development of bortezomib

Nature Reviews. Drug Discovery
Ibis Sánchez-Serrano

Abstract

The high price of many innovative drugs, which is in part due to the considerable expense and risk involved in drug development, underlines the need for more efficient approaches to bring drugs to the market, with more effective translational research in particular identified as an important part of such strategies. Here, the development of the cancer drug bortezomib (Velcade; Millennium Pharmaceuticals) by a biotechnology company - Myogenics/ProScript - started by academics from Harvard University is discussed to dissect the key academia-industry/public sector-private sector interactions that made the development of this drug a success despite many barriers. A model to explain how and why bortezomib was approved in record time is presented, and areas for public-policy initiatives to improve translational research in general are highlighted.

References

Apr 10, 1997·The New England Journal of Medicine·P J Barnes, M Karin
Oct 6, 1998·Annual Review of Biochemistry·A Hershko, A Ciechanover
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·V J PalombellaM B Grisham
Feb 21, 2002·The Oncologist·Julian Adams
Nov 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert Z OrlowskiSteven L Soignet
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
May 4, 2004·Nature Reviews. Cancer·Julian Adams
Oct 29, 2004·Nature Reviews. Cancer·Andrew C von Eschenbach
Feb 3, 2005·Nature Reviews. Molecular Cell Biology·Aaron Ciechanover
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators

❮ Previous
Next ❯

Citations

Sep 29, 2011·Cardiovascular Toxicology·Ajay GuptaSumit Sethi
Oct 9, 2012·Nature Medicine·Tom Maniatis
Jul 28, 2009·Cardiovascular Research·Nico P Dantuma, Kristina Lindsten
May 21, 2010·Molecular Cancer·Lidong ZhangW Roy Smythe
Apr 29, 2009·Expert Opinion on Therapeutic Targets·Sachiko Tsukamoto, Hideyoshi Yokosawa
Nov 1, 2009·Expert Review of Clinical Pharmacology·Thomas Senderovitz
Jul 1, 2006·Expert Opinion on Drug Discovery·Amit Banerjee
Dec 6, 2011·Biotechnology Advances·Fa-Ming ChenSongtao Shi
Dec 2, 2008·The Journal of Infection·J M San Roman MonteroA Gil de Miguel
Apr 15, 2008·Drug Discovery Today·Ruud E H M Smits, Wouter P C Boon
May 11, 2010·Bioorganic & Medicinal Chemistry Letters·Sachiko TsukamotoHideyoshi Yokosawa
Dec 19, 2012·Drug Discovery Today·C Simone Fishburn
Oct 13, 2009·Drug Discovery Today·Harald E HeemstraRemco L A de Vrueh
Nov 15, 2011·Cell·Noboru Mizushima, Masaaki Komatsu
Sep 2, 2008·Journal of Biomedical Informatics·Xiaoming WangOlufunmilayo I Olopade
Mar 11, 2017·The Journal of Infection·I Parent du ChateletD Lévy-Bruhl
Jan 24, 2019·Journal of Cancer Prevention·Ho Hee Jang
Oct 12, 2010·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Sachiko Tsukamoto
Jul 13, 2019·Rejuvenation Research·William Bains
Nov 8, 2017·Journal of Neuroengineering and Rehabilitation·David J ReinkensmeyerThomas Corfman
May 21, 2019·Expert Opinion on Drug Metabolism & Toxicology·Muhamed Baljevic, Robert Z Orlowski
Mar 31, 2017·Oncology Letters·Alessandro MorottiGiuseppe Saglio
May 29, 2018·Clinical Pharmacokinetics·Carlyn Rose C TanStefan K Barta
Apr 18, 2019·Drugs in R&D·Pawel Robak, Tadeusz Robak
Oct 2, 2019·International Journal of Molecular Sciences·Thanh Kieu HuynhWei-Chien Huang
Jul 22, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Romina A GuedesRita C Guedes
Mar 9, 2020·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Wenxiao JiangXueqiong Zhu
May 1, 2021·Journal of Clinical Medicine·Carl Christoph GoetzkeTilmann Kallinich
Aug 31, 2021·RSC Medicinal Chemistry·Saan Voss, Christoph Nitsche

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Ravi K AmaravadiEileen White
Nature Medicine
Heidi HörigFrancesco M Marincola
Clinical and Translational Science
Julian SolwayLainie F Ross
© 2021 Meta ULC. All rights reserved